January 23, 2013 at 14:46 PM EST
Alexion Says UK Unit Informed AGNSS Recommendation for Soliris Won't Be Followed
Alexion Pharma UK, a subsidiary of Alexion Pharmaceuticals, Inc. (NASDA: ALXN), has been informed by the National Specialised Commissioning Team (NSCT) that the Ministers of Health have decided to not follow a positive recommendation by the Advisory Group for National Specialised Services (AGNSS) when assessing Soliris® (eculizumab) as a treatment
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here